Elevated Capital Advisors LLC Increases Stock Position in Johnson & Johnson (NYSE:JNJ)

Elevated Capital Advisors LLC increased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 33.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,978 shares of the company’s stock after purchasing an additional 1,244 shares during the period. Elevated Capital Advisors LLC’s holdings in Johnson & Johnson were worth $720,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of JNJ. Seven Mile Advisory increased its position in Johnson & Johnson by 1.8% during the 2nd quarter. Seven Mile Advisory now owns 4,841 shares of the company’s stock worth $708,000 after purchasing an additional 84 shares in the last quarter. Wilkins Investment Counsel Inc. grew its holdings in shares of Johnson & Johnson by 5.6% during the second quarter. Wilkins Investment Counsel Inc. now owns 127,842 shares of the company’s stock worth $18,685,000 after buying an additional 6,768 shares in the last quarter. Rock Point Advisors LLC raised its position in shares of Johnson & Johnson by 1.2% in the second quarter. Rock Point Advisors LLC now owns 6,103 shares of the company’s stock valued at $892,000 after buying an additional 70 shares during the last quarter. Providence Wealth Advisors LLC boosted its position in Johnson & Johnson by 3.2% during the second quarter. Providence Wealth Advisors LLC now owns 9,440 shares of the company’s stock worth $1,390,000 after acquiring an additional 293 shares during the last quarter. Finally, Stevard LLC grew its stake in Johnson & Johnson by 2.7% in the 2nd quarter. Stevard LLC now owns 3,820 shares of the company’s stock worth $558,000 after acquiring an additional 100 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $144.50 on Tuesday. The company has a market capitalization of $347.90 billion, a price-to-earnings ratio of 20.91, a PEG ratio of 2.52 and a beta of 0.51. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85. The business has a 50-day moving average of $149.39 and a 200-day moving average of $156.10.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The company had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. During the same quarter last year, the company earned $2.66 earnings per share. Johnson & Johnson’s revenue for the quarter was up 5.2% on a year-over-year basis. On average, equities analysts anticipate that Johnson & Johnson will post 9.94 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.43%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is 71.78%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the purchase, the director now owns 1,000 shares in the company, valued at $147,220. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.16% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on JNJ shares. Wolfe Research initiated coverage on Johnson & Johnson in a report on Friday, November 15th. They set an “outperform” rating and a $190.00 price objective on the stock. Guggenheim lifted their price target on Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Citigroup cut their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. StockNews.com lowered shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, January 7th. Finally, Morgan Stanley lifted their price target on shares of Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Seven research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $174.71.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.